Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases

Tea Lamberg, Taina Sipponen, Sanna Valtanen, Kari K. Eklund, Tarja Mälkönen, Kristiina Aalto, Katriina Mikola, Kaija Leena Kolho, Sanna Leinonen, Pia Isomäki, Heidi Mäkinen, Krista Liisa Vidqvist, Arto Kokko, Laura Huilaja, Minna Kyllönen, Paula Keskitalo, Sirja Sard, Paula Vähäsalo, Ritva Koskela, Liisa KrögerPerttu Lahtinen, Anna Maija Haapala, Katja Korkatti, Tuulikki Sokka-Isler, T. Sakari Jokiranta

Tutkimustuotos: ArtikkeliScientificvertaisarvioitu

1 Lataukset (Pure)

Abstrakti

Introduction: The prevalence of immune-mediated diseases has increased in the past decades and despite the use of biological treatments all patients do not achieve remission. The aim of this study was to characterise the reasons for short interruptions during treatment with two commonly used TNF-inhibitors infliximab and adalimumab and to analyse the possible effects of the interruptions on immunisation and switching the treatment. Material and methods: This case-control study was based on retrospective analyses of patient records and a questionnaire survey to clinicians. A total of 370 patients (194 immunised cases and 172 non-immunised controls, 4 excluded) were enrolled from eight hospitals around Finland. Eleven different diagnoses were represented, and the largest patient groups were those with inflammatory bowel or rheumatic diseases. Results: Treatment interruptions were associated with immunisation in patients using infliximab (p <.001) or adalimumab (p <.000001). Patients with treatment interruptions were more likely to have been treated with more than one biological agent compared to those without treatment interruptions. This was particularly prominent among patients with a rheumatic disease (p <.00001). The most frequent reason for a treatment interruption among the cases was an infection, whereas among the control patients it was remission. The median length of one interruption was one month (interquartile range 1–3 months). Conclusion: Our results suggest that the interruptions of the treatment with TNF-inhibitors expose patients to immunisation and increase the need for drug switching. These findings stress the importance of careful judgement of the need for a short interruption in the biological treatment in clinical work, especially during non-severe infections.

AlkuperäiskieliEnglanti
Sivut275-284
JulkaisuAUTOIMMUNITY
Vuosikerta55
Numero5
DOI - pysyväislinkit
TilaJulkaistu - 2022
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Julkaisufoorumi-taso

  • Jufo-taso 1

!!ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Sormenjälki

Sukella tutkimusaiheisiin 'Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä